Medical Patent News

RSS

Dyadic International receives sixth USPTO patent

Dyadic International, Inc. a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, announced today that it has been issued U.S. Patent No. 7,794,962 by the United States Patent and Trademark Office.

14 Oct 2010

TrovaGene receives patent for diagnosis and monitoring of pathogenic infection

TrovaGene, Inc. a developer of transrenal molecular diagnostics to facilitate personalized medicine, received notice of U.S. Patent 7,803,929 entitled "Kits for diagnosis and monitoring of pathogenic infection by analysis of cell-free pathogenic nucleic acids in urine."

13 Oct 2010

TearLab receives patent for non-invasive tear collection platform

TearLab Corporation today announced that it has been granted U.S. Patent No. 7,810,380, entitled "Systems and methods for collecting tear film and measuring tear film osmolarity." This patent provides the company with broad and blocking intellectual property regarding the measurement of genetic and protein biomarkers within the tear film.

13 Oct 2010

Biomerix receives USPTO patent for Biomaterial tissue scaffold

Biomerix Corporation today announced that the United States Patent and Trademark Office (USPTO) has granted a patent for its proprietary biomaterial platform technology titled Reticulated elastomeric matrices, their manufacture and use in implantable devices.

13 Oct 2010

USPTO grants HemoShear patent for human cell-based surrogate systems

HemoShear LLC, a biotechnology research company and leading developer of human cell-based surrogate systems for discovery and assessment of new drug compounds, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,811,782 entitled "Use of An In Vitro Hemodynamic Endothelial/Smooth Muscle Cell Co-Culture Model to Identify New Therapeutic Targets for Vascular Disease."

13 Oct 2010

Lithera receives Notice of Allowance from USPTO for LIPO-102 patent application

Lithera, Inc. today announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application broadly covering compositions and methods of use associated with LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction.

13 Oct 2010

Immunomedics receives additional patent claims for antibody therapy

Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that additional claims for the patent family "Method and kit for imaging and treating organs and tissue," were issued as U.S. Patent No. 7,811,570.

13 Oct 2010

Auxilium receives USPTO patent for XIAFLEX product

Auxilium Pharmaceuticals, Inc. a specialty biopharmaceutical company, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 7,811,560 claiming, among other things, purified collagenase, the active component in Auxilium's product XIAFLEX (collagenase clostridium histolyticum).

13 Oct 2010

Proveris issues statement on Innova's sale of patent infringing ADSA system

“We are surprised and saddened that Innova has persisted in selling their infringing system”

12 Oct 2010

USPTO issues Watson Notice of Allowance for key progesterone patent to treat or prevent preterm birth

Columbia Laboratories, Inc. announced today that the U.S. Patent and Trademark Office (USPTO) has issued Watson Pharmaceuticals, Inc. a Notice of Allowance for a key patent for the use of progesterone to treat or prevent preterm birth. The USPTO issues a Notice of Allowance to report that a patent application has been examined and is allowed for issuance as a patent. The patent is expected to issue within three months upon payment of required fees.

12 Oct 2010

Essentialis receives patent for active component in DCCR product

Essentialis, Inc. announced today that the United States Patent & Trademark Office (USPTO) has issued U.S. Patent No. 7,799,777 entitled Salts of potassium ATP channel openers and uses thereof. The patent claims a novel composition of a polymorph of diazoxide choline, the active ingredient in the Essentialis lead product, DCCR. Essentialis has successfully completed phase 2b clinical trials with DCCR, showing a highly significant triglyceride reduction in dyslipidemic patients.

12 Oct 2010

Endo grants Watson royalty-free license to U.S. patents

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc. has reached a settlement with Endo Pharmaceuticals, Inc. on outstanding patent litigation related to Endo's Opana ER (Oxymorphone ER) product.

8 Oct 2010

ARCA receives European Patent for bucindolol based treatment for heart failure

ARCA biopharma, Inc. a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, today announced that the European Patent Office has issued a patent on methods of treating heart failure patients with bucindolol based on genetic targeting.

8 Oct 2010

GeoVax receives US Patent for pGA series of plasmids

GeoVax Labs, Inc., a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, has been issued via an exclusive license from Emory University, a US Patent for its "DNA expression vectors and methods of use. Issued on September 14, 2010, the patent claims cover novel vectors and novel HIV vaccine inserts.

7 Oct 2010

Affymax receives arbitration panel decision related to dispute against JNJ subsidiaries

Affymax, Inc. today announced that it has received a decision from the arbitration panel reviewing its dispute against certain subsidiaries of Johnson and Johnson (JNJ).

7 Oct 2010

Pioneer Surgical receives patent for nanOss technology

Pioneer Surgical Technology, Inc., a global medical device provider in orthopaedics, spine, and biologics, is proud to announce the United States Patent Office has reissued a patent further strengthening Pioneer's market position in nanocrystalline derived products used in orthopaedics.

6 Oct 2010

Integrity Engineering receives patent for innovative consumer device

Integrity Engineering, Inc. announced today that a U.S. Utility Patent was granted to Company principals and co-inventors Valerie Palfy and Don Skomsky, PE for an innovative consumer device for cleaning and sterilizing dental hardware such as retainers, mouth guards, plates and dentures.

5 Oct 2010

Intellect Neurosciences receives patent for Alzheimer's disease monoclonal antibody program

Intellect Neurosciences, Inc., a biopharmaceutical company with internal preclinical and clinical-stage pipelines, as well as multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a patent from the United States Patent and Trademark Office (USPTO) related to its internal Alzheimer's disease (AD) monoclonal antibody program.

5 Oct 2010

USPTO approves Microdroplet botulinum toxin treatment

The patent application for Microdroplet botulinum toxin, a treatment that improves facial features without detracting from facial expressiveness, has been allowed to inventor Dr. Kenneth D. Steinsapir, M.D. on September 2, 2010.

5 Oct 2010

$Osseon receives second patent NOA for spinal vertebral compression fracture technology$

Osseon receives second patent NOA for spinal vertebral compression fracture technology

Osseon Therapeutics, Inc., a biomedical device company based in Santa Rosa, California, received its second patent Notice of Allowance (NOA) for its spinal vertebral compression fracture (VCF) technology.

5 Oct 2010